Brokerages Set Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Price Target at $66.67

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) have received an average rating of “Hold” from the seven analysts that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have given a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $72.00.

A number of equities analysts have commented on RVPH shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research note on Tuesday, April 21st. Wall Street Zen upgraded shares of Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, July 5th.

Reviva Pharmaceuticals Stock Up 1.1%

NASDAQ RVPH opened at $0.51 on Friday. Reviva Pharmaceuticals has a 52 week low of $0.26 and a 52 week high of $17.20. The business’s fifty day simple moving average is $0.56 and its 200-day simple moving average is $1.68. The firm has a market cap of $6.69 million, a PE ratio of -0.13 and a beta of 0.53.

Reviva Pharmaceuticals (NASDAQ:RVPH) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.10). Research analysts expect that Reviva Pharmaceuticals will post -2.96 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC increased its stake in Reviva Pharmaceuticals by 6.9% during the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after acquiring an additional 29,063 shares during the last quarter. NewEdge Advisors LLC acquired a new position in shares of Reviva Pharmaceuticals in the 1st quarter valued at $58,000. XTX Topco Ltd lifted its stake in shares of Reviva Pharmaceuticals by 63.6% in the 4th quarter. XTX Topco Ltd now owns 164,291 shares of the company’s stock valued at $46,000 after purchasing an additional 63,893 shares during the last quarter. Lido Advisors LLC purchased a new position in shares of Reviva Pharmaceuticals during the 3rd quarter worth $37,000. Finally, Millennium Management LLC grew its holdings in shares of Reviva Pharmaceuticals by 15.0% during the 3rd quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock worth $631,000 after purchasing an additional 223,178 shares during the period. 63.18% of the stock is currently owned by hedge funds and other institutional investors.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.